Home » Stocks » PRNB

Principia Biopharma Inc. (PRNB)

Sep 25, 2020 - PRNB was delisted after being acquired by SNY
Stock Price: $100.05 USD 0.00 (0.00%)
Updated Sep 28, 2020 4:00 PM EDT
Market Cap 3.33B
Revenue (ttm) 50.00M
Net Income (ttm) -68.91M
Shares Out 33.09M
EPS (ttm) -2.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Sep 28, 2020
Last Price $100.05
Previous Close $100.05
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 99.95 - 100.37
Day's Volume 0
52-Week Range 25.35 - 101.89

News

Hide News
GlobeNewsWire - 3 months ago

Sanofi completes Principia Biopharma Inc. acquisition

Other stocks mentioned: SNY
GlobeNewsWire - 3 months ago

Sanofi announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), applicable to Sanofi’s proposed acquisition of Princi...

Other stocks mentioned: SNY
GlobeNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune me...

PRNewsWire - 4 months ago

SAN DIEGO, Sept. 12, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Principia Biopharma Inc.

PRNewsWire - 4 months ago

NEW YORK, Sept. 10, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: Principia Biopharma Inc.

GlobeNewsWire - 4 months ago

                                                                                                                                                            

Other stocks mentioned: SNY
Business Wire - 4 months ago

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Zacks Investment Research - 4 months ago

Principia (PRNB) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

PRNewsWire - 5 months ago

NEW YORK, Aug. 17, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Principia Biopharma Inc.

Newsfile Corp - 5 months ago

New York, New York--(Newsfile Corp. - August 17, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Principia Biopharma Inc.

Other stocks mentioned: SNY
PRNewsWire - 5 months ago

NEW YORK, Aug. 17, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in Ne...

The Motley Fool - 5 months ago

This isn't the pharmaceutical giant's only recent ride at the acquisition rodeo.

Other stocks mentioned: SNY
Business Wire - 5 months ago

TOKYO--(BUSINESS WIRE)--Financial executives at Oita Chuo Pacific Management have commented on Sanofi agreeing to acquire U.S. Principia Biopharma for $3.4 billion.

Other stocks mentioned: SNY
24/7 Wall Street - 5 months ago

Principia Biopharma Inc. (NASDAQ: PRNB) shares jumped to start out the week after it was announced that it would be acquired by Sanofi (NASDAQ: SNY).

Other stocks mentioned: SNY
Zacks Investment Research - 5 months ago

Sanofi (SNY) offers $3.68 billion to buy Principia Biopharma. The deal is likely to strengthen the company's core R&D areas of autoimmune and allergic diseases.

Other stocks mentioned: SNY
Investors Business Daily - 5 months ago

Sanofi is expanding efforts to combat MS and other autoimmune diseases by announcing a $3.68 billion acquisition of partner Principia Biopharma. The post Sanofi To Acquire Partner Principia Bi...

Other stocks mentioned: SNY
Invezz - 5 months ago

Sanofi S.A. (EPA: SAN) expressed plans of acquiring Principia Biopharma Inc.

Other stocks mentioned: SNY
Bloomberg Markets and Finance - 5 months ago

Sanofi to Buy Principia Biopharma in $3.4 Billion Deal

Aug.17 -- Sanofi has agreed to acquire Principia Biopharma Inc.

Other stocks mentioned: SNY
Benzinga - 5 months ago

Sanofi SA (NASDAQ: SNY) will acquire Principia Biopharma Inc (NASDAQ: PRNB) for $3.68 billion in cash, the two companies announced Monday.

Other stocks mentioned: SNY
CNBC - 5 months ago

French health care company Sanofi has agreed to buy U.S. company Principia Biopharma for around $3.7 billion, the companies said on Monday, strengthening Sanofi's presence in research and deve...

Other stocks mentioned: SNY
GlobeNewsWire - 5 months ago

Sanofi to acquire Principia Biopharma  

Other stocks mentioned: SNY
Zacks Investment Research - 5 months ago

Principia Biopharma Inc. (PRNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Zacks Investment Research - 6 months ago

Principia Biopharma (PRNB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

GlobeNewsWire - 6 months ago

Dosing of Patient Will Trigger $50 Million Milestone Payment Dosing of Patient Will Trigger $50 Million Milestone Payment

GlobeNewsWire - 7 months ago

Clear dose-response combined with decreased daily corticosteroid usage

GlobeNewsWire - 7 months ago

Oral BTK inhibitor reaches primary endpoint in 50 percent of patients treated > 12 weeks; demonstrates fast onset and durable responses

GlobeNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., May 26, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-medi...

Zacks Investment Research - 8 months ago

Principia Biopharma Inc. (PRNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Zacks Investment Research - 10 months ago

Principia Biopharma Inc. (PRNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 1 year ago

Company expands focus on immune-mediated diseases and  suspends FGFR program

GlobeNewsWire - 1 year ago

Company’s lead candidate PRN1008 receives generic name -- rilzabrutinib

GlobeNewsWire - 1 year ago

Accelerated enrollment of company’s Phase 3 pivotal trial anticipating final results in second half of 2021 Accelerated enrollment of company’s Phase 3 pivotal trial anticipating final results...

Investors Business Daily - 1 year ago

Principia Biopharma stock has rocketed 31% this week amid enthusiasm for its technology, BTK inhibition — highlighted by notable moves from pharmaceutical giants Merck and Sanofi.

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immun...

Zacks Investment Research - 1 year ago

Principia Biopharma Inc. (PRNB) delivered earnings and revenue surprises of -9.41% and -100.00%, respectively, for the quarter ended September 2019.

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immun...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immun...

GlobeNewsWire - 1 year ago

Preliminary results from trial have been accepted as an oral presentation at upcoming American Society of Hematology Annual Meeting Preliminary results from trial have been accepted as an oral...

GlobeNewsWire - 1 year ago

Consistent efficacy and safety profile for pemphigus patients observed

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral thera...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral thera...

Seeking Alpha - 1 year ago

Undercovered stock with strong potential in developing next-generation BTK inhibitors.

About PRNB

Principia Biopharma, a late-stage biopharmaceutical company, focuses on developing novel therapies for immune-mediated diseases. The company is developing rilzabrutinib, an inhibitor that is in Phase III clinical trials for the treatment of pemphigus, a chronic skin disease, as well as and pemphigus foliaceus; in a Phase 1/2 trial for the treatment of immune thrombocytopenia; and a Phase 2 trial for the treatment of IgG4-related disease. It is also developing PRN2246/SAR442168, an inhibitor, which is in Phase Ii clinical trial for treating mult... [Read more...]

Industry
Biotechnology
IPO Date
Sep 14, 2018
CEO
Martin Babler
Employees
124
Stock Exchange
NASDAQ
Ticker Symbol
PRNB
Full Company Profile

Financial Performance

Financial Statements